5 Key Market Insights for Thursday’s Opening

As the markets brace for a potentially volatile trading session, investors are closely watching the unfolding geopolitical tensions and key economic indicators. Today marks the one-year anniversary of President Donald Trump’s initial tariff announcement, an event he termed “liberation day.” Despite the milestone, stock futures are signaling a dip this morning, following a string of winning days for the three major indexes.

Here are five crucial updates shaping the trading day:

President Trump’s primetime address concerning the Iran conflict last night appears to have provided little solace to Wall Street. Stock futures tumbled, and oil prices surged following the President’s stern declaration that the U.S. would inflict “extremely hard” strikes on Iran over the next two to three weeks, diminishing hopes for an immediate resolution.

Key takeaways from the address include:

• In his approximately 20-minute speech, Trump underscored the conflict’s proximity to an end, stating that if a resolution isn’t reached within the next two to three weeks, the U.S. might target Iran’s oil infrastructure.
• Notably absent from the address were any mentions of ongoing negotiations or plans for deploying ground troops, both of which have been considered potential pathways to de-escalating the conflict.
• The President acknowledged the strain on American consumers facing the highest energy prices in years, attributing the surge to the Iranian regime’s “deranged terror attacks against commercial oil tankers and neighboring countries.”
• The market’s reaction has been swift, with stock futures declining and oil prices experiencing a significant surge of approximately 8% in early trading.
• The stock market will be closed tomorrow in observance of Good Friday. However, a special edition of CNBC’s “Squawk Box” at 8 a.m. ET will provide comprehensive coverage of the March jobs report.

Sources have informed CNBC that SpaceX has confidentially filed for its long-anticipated Initial Public Offering (IPO), signaling a significant step towards what is widely expected to be a record-breaking public market debut for the Elon Musk-led aerospace giant. This confidential filing allows SpaceX to share its financial data with the Securities and Exchange Commission (SEC) prior to its public disclosure. However, the company will still be required to submit a public filing at least 15 days before initiating its roadshow.

Reports from Bloomberg, citing individuals familiar with the matter, suggest that SpaceX could aim for a valuation of $1.75 trillion and potentially list around June. If this IPO materializes, it would mark a historic achievement for Elon Musk, positioning him as the first individual to lead two separate, publicly traded companies each valued at over a trillion dollars. This move underscores SpaceX’s impressive growth trajectory and its potential to disrupt established industries, from satellite internet to space exploration.

Republican leadership in Congress has indicated their support for a two-track funding plan for the Department of Homeland Security (DHS), effectively reverting to a Senate-approved proposal that was previously rejected by House Republicans. This bipartisan approach aims to allocate funds for the majority of the department’s operations, including the Transportation Security Administration (TSA), while deferring the contentious debate over immigration enforcement to a later date. This development comes after President Trump had announced his intention to ensure TSA agents were paid via executive order, a move that is reportedly being funded through a provision in the “One Big Beautiful Bill Act.” The resolution of this funding impasse is crucial for ensuring the continuity of essential government services and averting potential disruptions.

Eli Lilly has secured U.S. Food and Drug Administration (FDA) approval for its new GLP-1 pill, Foundayo, marking a significant advancement in the burgeoning weight loss drug market. This approval is poised to intensify the competitive landscape between Eli Lilly and its rival Novo Nordisk, as both pharmaceutical giants vie for dominance in this lucrative new frontier. Foundayo, a once-daily pill, is slated to begin shipping through Eli Lilly’s direct-to-consumer platform next week, with broader availability expected later.

The pricing structure for Foundayo reveals a tiered approach: insured patients could pay as little as $25 per month with a coupon, while uninsured individuals might face a cost of up to $349. In a recent interview, Eli Lilly CEO Dave Ricks voiced his opposition to the White House’s proposed “most favored nation” drug pricing policy, expressing concerns that such measures could potentially stifle future drug development and innovation by impacting research and development investments.

Sam’s Club is implementing its first membership fee increase since 2022, with its annual membership costs set to rise by $10 starting next month. The basic and premium membership tiers will now be priced at $60 and $120, respectively. Despite this adjustment, Sam’s Club’s membership fees remain more competitive than those of rival Costco. The company cited enhanced member benefits, including extended operating hours and improvements in pickup and delivery services, as justifications for the price hike. This move by Sam’s Club reflects a strategic effort to enhance value proposition for its members while optimizing revenue streams in a competitive retail environment.

Here are additional insights and stories to consider over the extended weekend: